The global hyaluronidase market size is expected to reach USD 1,734.6 million by 2030 growing at a CAGR of 8.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The significance of minimally invasive cosmetic procedures has increased considerably over the years and various demographic research studies have been conducted to evaluate the adoption pattern of cosmetic treatments across the globe, especially in developed countries.
Hyaluronic acid fillers form the most important component of minimally invasive aesthetic procedures carried out across the globe. Since hyaluronidase is mostly preferred while conducting these procedures, a growing number of minimally invasive aesthetic surgeries are expected to positively impact market growth. Dermal fillers have significant applications in minimally invasive facial aesthetic procedures, which has also led to an increase in the number of reported complications.
Clinicians are required to be entirely aware of the symptoms associated with hyaluronic acid injection complications in order to treat them effectively. It is crucial to establish effective protocols of action suitable for emergencies wherein the desired agents are readily available at the site of surgery or treatment. This aids in controlling the adverse impact of hyaluronic acid filler injections.
Hyaluronidase Market Report Highlights
- Animal derived hyaluronidase segment held the largest revenue share of 67.0% in 2022 and are anticipated to maintain this trend throughout the forecast period
- Synthetic hyaluronidase segment is anticipated to register the fastest CAGR of 9.4% over the forecast period
- The Dermatology segment held the largest revenue share of approximately 44.6% in 2022
- The chemotherapy segment is estimated to register the fastest CAGR of 10.5% over the forecast period.
- North America dominated the market in 2022 with the largest revenue share of 38.0% due to the high penetration of novel cosmetic treatments. In addition, dermatologists in this region are developing new non-surgical cosmetic procedures and hyaluronidase-based injectables which are among the highly recommended injectable dermal fillers
- Asia Pacific is projected to witness the fastest growth owing to the numerous untapped growth opportunities in hyaluronidase-based treatments
- A robust network of local manufacturers has significantly contributed to the revenue generated from this region
Get a preview of the latest developments in the Hyaluronidase Market? Download your FREE sample PDF copy today and explore key data and trends
Hyaluronidase Market Segmentation
Grand View Research has segmented the global hyaluronidase market on the basis of type, application, and region:
Hyaluronidase Type Outlook (Revenue, USD Million, 2018 - 2030)
- Animal-derived Hyaluronidase
- Synthetic Hyaluronidase
Hyaluronidase Application Outlook (Revenue, USD Million, 2018 - 2030)
- Dermatology
- Chemotherapy
- Ophthalmology
- Plastic Surgery
- Others
Hyaluronidase Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Sweden
- Norway
- Denmark
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Key Players in the Hyaluronidase Market
- Amphastar Pharmaceuticals, Inc.
- PrimaPharma, Inc.
- Halozyme, Inc.
- Bausch & Lomb Incorporated
- The Cooper Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- STEMCELL Technologies Inc.
- Shreya Life Sciences Pvt. Ltd.
Order a free sample PDF of the Hyaluronidase Market Intelligence Study, published by Grand View Research.